On September 15, the medical sector showed widespread gains, with China's largest medical ETF (512170) fluctuating upward, rising over 1% intraday and recording trading volume exceeding 460 million yuan.
Notably, the Medical ETF (512170) has been attracting continuous capital inflows recently. As of September 12, it has attracted a total of 380 million yuan over four consecutive days. The fund's latest scale stands at 275.84 billion yuan, ranking first among similar ETFs.
Among constituent stocks, CXO companies performed exceptionally well, with Joinn Laboratories hitting the daily limit up, followed by Pharmaron and Jiuzhou Pharmaceutical, which gained 6.37% and 3.95% respectively. On the other hand, BGI Genomics, WiSoft Technology, and MGI Tech showed weaker performance, declining 2.91%, 2.38%, and 1.93% respectively.
A research report from Wanlian Securities noted that in the first half of 2025, the overall revenue of the medical R&D outsourcing CXO sector grew 13.77% year-over-year, with net profit attributable to shareholders increasing 63.82% year-over-year. The recovery in global investment and financing in the first half of 2025 drove demand for front-end drug discovery, shortened CRO (Contract Research Organization) business order conversion cycles, and boosted performance realization.
On the industry news front, between September 1-15, 2025, over 400 Class I investigational new drugs were in clinical development in the innovative drug sector, while over 1,800 Class II and III medical device products received marketing approval.
Cinda Securities pointed out that in the high-end medical device sector, recovery in hospital procurement is driving growth, consumer medical demand is gradually recovering, overseas orders are recovering, and penetration rates of high-end consumables are increasing. AI healthcare focuses on cutting-edge areas such as imaging, medical testing, and gene sequencing, with the National High-Performance Medical Device Innovation Center launching evaluations to drive industry transformation. The pharmaceutical and biotechnology sector valuation is at historical lows, with marginal improvement in corporate performance, favoring high-end devices and AI healthcare directions.
The Medical ETF (512170) and its off-exchange feeder fund (012323) passively track the CSI Healthcare Index. The index's top ten weighted stocks are WuXi AppTec, Mindray Medical, United Imaging Healthcare, Aier Eye Hospital Group, Tiger Medical, Aimei, Pharmaron, Lepu Medical, New Industries Biomedical Engineering, and Huatai Medical.
Data sourced from Shanghai and Shenzhen stock exchanges and public information.
Risk Warning: The above products are issued and managed by fund management companies, and distributors do not assume responsibility for product investment, redemption, and risk management. Investors should carefully read fund legal documents such as the "Fund Contract," "Prospectus," and "Fund Product Summary" to understand the fund's risk-return characteristics and choose products that match their risk tolerance. Past fund performance does not predict future performance, and fund investment requires caution! Sales organizations (including fund management company direct sales organizations and other sales organizations) conduct risk assessments of funds according to relevant laws and regulations. Investors should pay attention to suitability opinions issued by fund management companies. Suitability opinions from various sales organizations are not necessarily consistent, and fund product risk level evaluations by fund sales organizations cannot be lower than those made by fund management companies. Differences exist between fund risk-return characteristics and fund risk levels in fund contracts due to different considerations. Investors should understand fund risk-return situations and carefully select fund products based on their investment objectives, terms, investment experience, and risk tolerance, bearing risks independently. Registration of the above funds by the China Securities Regulatory Commission does not indicate substantial judgment or guarantee of their investment value, market prospects, and returns. Fund investment requires caution.
MACD golden cross signal formed, these stocks show good upward momentum!
Comments